So I used the plugin for some time now and it works just fine.
This time I have this mermaid code but it doesn’t seem to work. Can some help identify the problem here?
flowchart TD
A[Relapsed/Refractory AML<br/>Confirm diagnosis & molecular profiling] --> B{Patient Fitness<br/>Assessment}
B -->|Fit for Intensive Therapy| C[Fit for Intensive<br/>Chemotherapy]
B -->|Unfit for Intensive Therapy| D[Unfit for Intensive<br/>Chemotherapy]
C --> E{Actionable<br/>Mutations?}
E -->|Yes| F[Targeted Therapy<br/>• FLT3: Gilteritinib<br/>• IDH1: Ivosidenib<br/>• IDH2: Enasidenib<br/>• KMT2Ar: Revumenib<br/>± Chemotherapy]
E -->|No| G[Salvage Chemotherapy<br/>• FLAG-IDA<br/>• CLAG-M<br/>• MEC/ICE<br/>• High-dose Ara-C]
D --> H[Low-Intensity Options<br/>• Venetoclax + HMA<br/>• Venetoclax + LDAC<br/>• Targeted agents<br/>• Clinical trials<br/>• Palliative care]
F --> I{Response<br/>Assessment<br/>CR/CRi achieved?}
G --> I
H --> I
I -->|Complete Remission| J[Complete Remission<br/>Consider alloHSCT<br/>if suitable donor<br/>and patient fit]
I -->|No Response/PD| K[No Response/<br/>Progressive Disease<br/>• Clinical trials<br/>• Alternative salvage<br/>• Palliative care]
J --> L[Allogeneic HSCT<br/>Curative Intent]
L --> M[Post-HSCT Management<br/>• Monitor for relapse<br/>• DLI if relapsed<br/>• Maintenance therapy<br/>• Second alloHSCT]
K --> N[Clinical Trials Preferred<br/>• CAR-T therapy<br/>• Novel agents<br/>• Combination therapies]
%% Special considerations box
O[Special Considerations:<br/>• Prior HMA/Venetoclax: Alternative mechanisms<br/>• Extramedullary disease: Radiation therapy<br/>• CNS involvement: Intrathecal + high-dose systemic<br/>• Duration of first remission affects choice<br/>• Molecular MRD monitoring<br/>• Supportive care throughout]
%% FDA approved agents box
P[FDA-Approved Targeted Agents 2024-2025:<br/>FLT3: Gilteritinib ADMIRAL<br/>IDH1: Ivosidenib<br/>IDH2: Enasidenib<br/>KMT2Ar: Revumenib Nov 2024<br/>CD33: Gemtuzumab ozogamicin<br/>BCL-2: Venetoclax combinations]
%% Treatment goals
Q[Treatment Goals:<br/>• Bridge to alloHSCT<br/>• Achieve durable remission<br/>• Improve quality of life<br/>• Extend overall survival]
%% Style definitions
classDef startEnd fill:#e1f5fe,stroke:#01579b,stroke-width:2px
classDef decision fill:#fff3e0,stroke:#e65100,stroke-width:2px
classDef treatment fill:#e8f5e8,stroke:#2e7d32,stroke-width:2px
classDef targeted fill:#ffebee,stroke:#c62828,stroke-width:2px
classDef endpoint fill:#f3e5f5,stroke:#7b1fa2,stroke-width:2px
classDef info fill:#f5f5f5,stroke:#616161,stroke-width:1px
%% Apply styles
class A startEnd
class B,E,I decision
class C,D,G,H,K,M,N treatment
class F targeted
class J,L,Q endpoint
class O,P info
```mermaid